The PROTAC milestone
A new drug class called PROTACs showed promise in breast cancer, with the first FDA-approved version outperforming existing options in a difficult-to-treat patient group.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
GLP-1-based incretin therapy is associated with lower incident…
Adults taking GLP-1 diabetes medications showed a 54% lower risk of Alzheimer's disease compared to those on other diabetes treatments in a large study.
Near-term implementable findingEffect of tirzepatide and semaglutide on blood pressure
Tirzepatide and semaglutide affect blood pressure differently—one reduces hypertension risk substantially but may cause low blood pressure at higher doses, while the other stays neutral.
Early cancer detection or preventionUltra-low-pass whole-genome sequencing of bile cfDNA in patients with…
A new genetic test of bile samples collected during routine procedures detected bile duct and pancreatic cancers an average of 38 days earlier than current methods.
Novel or significantly improved treatmentEpigenetic Priming with Azacitidine Prior to Allogeneic Hematopoietic…
Pre-transplant treatment with azacitidine showed encouraging survival outcomes and identified a molecular marker linking treatment response to relapse prevention in blood cancer patients.